Prosecution Insights
Last updated: October 02, 2026
Application No. 18/855,856

NOVEL LIPASE

Non-Final OA §101
Filed
Oct 10, 2024
Priority
Apr 13, 2022 — JP 2022-066572 +1 more
Examiner
NOAKES, SUZANNE MARIE
Art Unit
Tech Center
Assignee
Kao Corporation
OA Round
1 (Non-Final)
73%
Grant Probability
Favorable
1-2
OA Rounds
7m
Est. Remaining
92%
With Interview

Examiner Intelligence

Grants 73% — above average
73%
Career Allowance Rate
788 granted / 1075 resolved
+13.3% vs TC avg
Strong +18% interview lift
Without
With
+18.2%
Interview Lift
resolved cases with interview
Typical timeline
2y 7m
Avg Prosecution
51 currently pending
Career history
1118
Total Applications
across all art units

Statute-Specific Performance

§101
6.3%
-33.7% vs TC avg
§103
24.5%
-15.5% vs TC avg
§102
23.0%
-17.0% vs TC avg
§112
30.0%
-10.0% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1075 resolved cases

Office Action

§101
DETAILED ACTION Notice of AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Status of Application Claims 1-11 are pending and subject to examination on the merits. Priority The instant application is a 371 of PCT/JP2023/014863 filed 12 April 2023 which claims benefit of foreign priority document JP 2022-066572 filed 13 April 2022 is acknowledged. Said document has been received. Information Disclosure Statement The information disclosure statements (IDS) submitted on 29 April 2026 and 10 October 2024 have been considered by the examiner. See initialed and signed PTO/SB/08’s. Claim Rejections - 35 USC § 101 35 U.S.C. 101 reads as follows: Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title. Claims 1-10 are rejected under 35 U.S.C. 101 because the claimed invention is directed to a judicial exception (i.e., a natural phenomenon) without additional elements that integrate the judicial exception into a practical application. An analysis with respect to the claims as a whole reveals that they do not include additional elements that integrate the judicial exception into a practical application. See MPEP 2106. Analysis of subject-matter eligibility under 35 U.S.C. § 101 requires consideration of the following steps: Step (1) whether the claim is directed to one of the four categories recited in §101 (process, machine, manufacture or composition of matter); Step (Revised 2A - Prong 1) do the claims recite an abstract idea (mathematical concepts, mental processes or method of organizing human activity), law of nature or natural phenomenon; Step (Revised 2A - Prong 2) do the claims recite additional elements that integrate the judicial exception into a practical application; and Step (2B) whether the claim as a whole recites something that amounts to significantly more than the judicial exception. (See 2019 Revised Patent Subject Matter Eligibility Guidance (2019 PEG)). Step 1: Yes; the claims are directed to a composition of matter. Step 2A – Prong 1: Yes, the claims recite a natural phenomenon, namely, a naturally occurring product/protein, naturally occurring polynucleotide encoding the protein and cell comprising either or both. Step 2A – Prong 2: No, the claims do not recite any additional elements that integrate the judicial exception into a practical application because the claims appear to be merely drawn to what already exists in nature. The lipase of SEQ ID NO: 14 is termed “KAL-A” throughout the specification. It does not appear that anything has been done to a pre-existing lipase to make instant SEQ ID NO: 14. Rather it appears said lipase has been isolated and “found” from a naturally occurring source (See paragraph 0023 of PG-Pub). As such, there is nothing in the claims which differentiates this naturally occurring enzyme in terms of structure and/or function. Thus, there is ultimately nothing in the claims which integrates the judicial exception into a practical application. This holds true for the polynucleotide encoding the lipase, which would be a naturally occurring polynucleotide or DNA fragment comprising said polynucleotide (claims 2-3). The cell “transformed” with the lipase does not differentiate the naturally occurring cells which produce said lipase (claims 4-5). In addition, the claimed cleaning composition(s) comprising said lipase are merely an intended use and is recited at such a high level of generality that there is nothing in said cleaning compositions to transform the claimed lipase into something different that which naturally occurs (claims 6-10). Step 2B: As noted in answering that of 2A – Prong 2 above, there is nothing in the claims which amounts to significantly more in terms of structure and/or function and the claims read on naturally occurring enzymes. Thus, the claims are drawn to a judicial exception, namely, a naturally occurring product. Conclusion Claims 1-10 are rejected. Claim 11 is objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. Any inquiry concerning this communication or earlier communications from the examiner should be directed to SUZANNE M NOAKES whose telephone number is (571)272-2924. The examiner can normally be reached M-F (7-4). Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Manjunath Rao can be reached at 571-272-0939. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /SUZANNE M NOAKES/Primary Examiner, Art Unit 1656 26 June 2026
Read full office action

Prosecution Timeline

Oct 10, 2024
Application Filed
Jun 30, 2026
Non-Final Rejection mailed — §101
Sep 15, 2026
Examiner Interview Summary
Sep 15, 2026
Applicant Interview (Telephonic)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12747416
CLEANING COMPOSITIONS COMPRISING DISPERSINS VI
4y 3m to grant Granted Sep 29, 2026
Patent 12747469
DNA POLYMERASE VARIANT WITH IMPROVED DISCRIMINATION OF GENETIC VARIANTS
3y 3m to grant Granted Sep 29, 2026
Patent 12742160
GENETIC ENGINEERING OF FUNGI TO MODULATE TRYPTAMINE EXPRESSION
4y 5m to grant Granted Sep 22, 2026
Patent 12744230
ELECTRON CARRIER, ELECTRON CARRIER PRODUCTION METHOD, AND ELECTRON TRANSFER METHOD
4y 4m to grant Granted Sep 22, 2026
Patent 12740996
CANCER-SPECIFIC TRANS-SPLICING RIBOZYME EXPRESSING IMMUNE CHECKPOINT INHIBITOR, AND USE THEREOR
3y 4m to grant Granted Sep 22, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
73%
Grant Probability
92%
With Interview (+18.2%)
2y 7m (~7m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1075 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month